Page last updated: 2024-11-04

vorinostat and Hypothyroidism

vorinostat has been researched along with Hypothyroidism in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Hypothyroidism: A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kim, DW1
Park, JW1
Willingham, MC1
Cheng, SY1

Other Studies

1 other study available for vorinostat and Hypothyroidism

ArticleYear
A histone deacetylase inhibitor improves hypothyroidism caused by a TRĪ±1 mutant.
    Human molecular genetics, 2014, May-15, Volume: 23, Issue:10

    Topics: Adipogenesis; Animals; CCAAT-Enhancer-Binding Proteins; Drug Evaluation, Preclinical; Epigenesis, Ge

2014